Abstract
The human epidermal growth factor receptor (EGFR) biology is not completely explained; however EGFRtargeting has formed the basis of extensive and growing drug development. Inhibition of receptor tyrosine kinase activity involved in the EGFR signalling cascade is a fundamental mechanism for the use of EGFR specific tyrosine kinase (TK) inhibitors exemplified by gefitinib (ZD1839, Iressa) and erlotinib (OSI-774, Tarceva). Despite initially promising results in chemotherapy-resistant patients with non small cell lung cancer (NSCLC), disappointing results from phase III trials of gefitinib in NSCLC have been of concern of some. When EGFR-targeting drugs were introduced into the clinic, the specific targets affected in human tumors were unknown. Recently, different studies reported that mutations in the TK domain of EGFR are strongly associated with gefitinib- or erlotinib-sensitivity in patients with NSCLC. This article reviews the rationale for targeting EGFR by TK inhibitors, the discovery of EGFR mutations and subsequent studies to define the incidence, spectrum and functions of EGFR mutations. This paper represents the effort of a lung cancer focused translational research team made up of molecular biologists, medical oncologists and thoracic surgeons. The final objective is to achieve a comprehensive, but simple, review of the current status of the shift from cytotoxic to molecularly targeted therapy in lung cancer treatment potentially useful in the planning of translational research trials.
Keywords: EGFR family, Non-small cell lung cancer (NSCLC), cell proliferation, Gefitinib, OSI-774
Current Respiratory Medicine Reviews
Title: Role of Tyrosine Kinase Inhibitor Molecules in Non Small Cell Lung Cancer:From Benchside to Bedside
Volume: 3 Issue: 2
Author(s): Alessia Catassi, Alfredo Cesario, Pierluigi Granone and Patrizia Russo
Affiliation:
Keywords: EGFR family, Non-small cell lung cancer (NSCLC), cell proliferation, Gefitinib, OSI-774
Abstract: The human epidermal growth factor receptor (EGFR) biology is not completely explained; however EGFRtargeting has formed the basis of extensive and growing drug development. Inhibition of receptor tyrosine kinase activity involved in the EGFR signalling cascade is a fundamental mechanism for the use of EGFR specific tyrosine kinase (TK) inhibitors exemplified by gefitinib (ZD1839, Iressa) and erlotinib (OSI-774, Tarceva). Despite initially promising results in chemotherapy-resistant patients with non small cell lung cancer (NSCLC), disappointing results from phase III trials of gefitinib in NSCLC have been of concern of some. When EGFR-targeting drugs were introduced into the clinic, the specific targets affected in human tumors were unknown. Recently, different studies reported that mutations in the TK domain of EGFR are strongly associated with gefitinib- or erlotinib-sensitivity in patients with NSCLC. This article reviews the rationale for targeting EGFR by TK inhibitors, the discovery of EGFR mutations and subsequent studies to define the incidence, spectrum and functions of EGFR mutations. This paper represents the effort of a lung cancer focused translational research team made up of molecular biologists, medical oncologists and thoracic surgeons. The final objective is to achieve a comprehensive, but simple, review of the current status of the shift from cytotoxic to molecularly targeted therapy in lung cancer treatment potentially useful in the planning of translational research trials.
Export Options
About this article
Cite this article as:
Catassi Alessia, Cesario Alfredo, Granone Pierluigi and Russo Patrizia, Role of Tyrosine Kinase Inhibitor Molecules in Non Small Cell Lung Cancer:From Benchside to Bedside, Current Respiratory Medicine Reviews 2007; 3 (2) . https://dx.doi.org/10.2174/157339807780599135
DOI https://dx.doi.org/10.2174/157339807780599135 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synthesis of Novel Coumarin Derivatives 7,8-Fused onto Thiazole
Letters in Organic Chemistry Radiolabeled Small Molecule Inhibitors of VEGFR - Recent Advances
Current Pharmaceutical Design Fluorescent Immortalized Human Adipose Derived Stromal Cells (hASCs-TS/GFP+) for Studying Cell Drug Delivery Mediated by Microvesicles
Anti-Cancer Agents in Medicinal Chemistry Metabolomics of Exhaled Breath Condensate by Nuclear Magnetic Resonance Spectroscopy and Mass Spectrometry: A Methodological Approach
Current Medicinal Chemistry Neuroinflammation: A Therapeutic Target of Cotinine for the Treatment of Psychiatric Disorders?
Current Pharmaceutical Design TGF-beta Signaling in Cancer Treatment
Current Pharmaceutical Design Apoptotic Effects of Melittin on 4T1 Breast Cancer Cell Line is associated with Up Regulation of Mfn1 and Drp1 mRNA Expression
Anti-Cancer Agents in Medicinal Chemistry Cancer Stem Cells in Hematological Disorders: Current and Possible New Therapeutic Approaches
Current Pharmaceutical Biotechnology Genetic Variation at the Human MGMT Locus and its Biological Consequences
Current Pharmacogenomics Anticancer Mammalian Target of Rapamycin (mTOR) Signaling Pathway Inhibitors: Current Status, Challenges and Future Prospects in Management of Epilepsy
CNS & Neurological Disorders - Drug Targets Neuropilin and Neuropilin Associated Molecules as New Molecular Targets in Pancreatic Adenocarcinoma
Anti-Cancer Agents in Medicinal Chemistry Synthesis, Biological Evaluation and Molecular Docking Studies of Pyridine Incorporated Chalcone Derivatives as Anticancer Agents
Letters in Organic Chemistry Retrospective Observational Study to Evaluate Causality, Preventability and Severity of Adverse Drug Reaction Associated with Anticancer Drugs in a Tertiary Care Hospital in Northern India
Current Drug Safety Preface
Current Proteomics DNA Methyltransferases Inhibitors from Natural Sources
Current Topics in Medicinal Chemistry Origins and Consequences of AID Expression in Lymphoid Neoplasms
Current Immunology Reviews (Discontinued) Quantitative Structure-Activity Relationships for Anticancer Activity of 2- Phenylindoles Using Mathematical Molecular Descriptors
Current Computer-Aided Drug Design Studies on Anticancer Activities of Lactoferrin and Lactoferricin
Current Protein & Peptide Science Involvement of Cannabinoids in Cellular Proliferation
Mini-Reviews in Medicinal Chemistry Embryonic Stem Cell MicroRNAs: Defining Factors in Induced Pluripotent (iPS) and Cancer (CSC) Stem Cells?
Current Stem Cell Research & Therapy